Payment overview · 2025
General Payments
$81.52
4 reported records · 3 companies
Healthcare provider profile · identity verified
Thomas J Panasci, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DES PERES, MO · NPI 1629051081
Verified facts
What the public records show
CMS Open Payments records show Thomas J Panasci, M.D. received $81.52 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 54.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.07 | 54.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.56 | 25.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.89 | 20.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $81.52 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.07 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.07 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 110 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
110 | 110 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
111 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 867 | 250 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 642 | 212 |
| Levothyroxine Sodium | Levothyroxine Sodium | 540 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 459 | 134 |
| Lisinopril | Lisinopril | 415 | 124 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 254 | 76 |
| Metformin Hcl | Metformin Hcl | 245 | 73 |
| Omeprazole | Omeprazole | 234 | 69 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 231 | 54 |
| Alprazolam | Alprazolam | 219 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 59 |
| Losartan Potassium | Losartan Potassium | 181 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 179 | 69 |
| Sertraline Hcl | Sertraline Hcl | 167 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 60 |
| Trazodone Hcl | Trazodone Hcl | 136 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 40 |
| Tramadol Hcl | Tramadol Hcl | 133 | 39 |
| Montelukast Sodium | Montelukast Sodium | 117 | 38 |
| Allopurinol | Allopurinol | 115 | 28 |
| Jardiance | Empagliflozin | 113 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 28 |
| Eliquis | Apixaban | 111 | 22 |
| Gabapentin | Gabapentin | 111 | 32 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 110 | 110 |
| Finasteride | Finasteride | 106 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 31 |
| Irbesartan | Irbesartan | 102 | 31 |
| Furosemide | Furosemide | 94 | 32 |
| Simvastatin | Simvastatin | 80 | 27 |
| Baclofen | Baclofen | 78 | 32 |
| Famotidine | Famotidine | 74 | 25 |
| Metformin Hcl Er | Metformin Hcl | 73 | 31 |
| Diazepam | Diazepam | 68 | 16 |
| Clonazepam | Clonazepam | 64 | 15 |
| Ozempic | Semaglutide | 62 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 22 |
| Mounjaro | Tirzepatide | 61 | 13 |
| Prednisone | Prednisone | 61 | 47 |
| Valsartan | Valsartan | 55 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Meloxicam | Meloxicam | 53 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 18 |
| Ramipril | Ramipril | 49 | 14 |
| Bupropion Xl | Bupropion Hcl | 44 | 15 |
| Glimepiride | Glimepiride | 44 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 12 |
| Donepezil Hcl | Donepezil Hcl | 43 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Carvedilol | Carvedilol | 41 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 38 |
| Synthroid | Levothyroxine Sodium | 40 | 12 |
| Atenolol | Atenolol | 39 | suppressed |
| Potassium Chloride | Potassium Chloride | 39 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | 14 |
| Temazepam | Temazepam | 38 | suppressed |
| Mupirocin | Mupirocin | 37 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 11 |
| Alendronate Sodium | Alendronate Sodium | 35 | 14 |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 11 |
| Celecoxib | Celecoxib | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Lorazepam | Lorazepam | 32 | 15 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Fentanyl | Fentanyl | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Lyrica | Pregabalin | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $81.52 · 4 records | ABBVIE INC. | ABRYSVO, AREXVY, COMIRNATY, PREVNAR 20, QULIPTA, SHINGRIX, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error